In this debut episode of The UroOnc Minute, host Adam Weiner, MD, a urologic oncologist and surgeon-scientist at Cedars-Sinai Medical Center, introduces listeners to a new Urology Times podcast ...

The phase 3 PRESTO trial (NCT03009981) assessed combined androgen signaling blockade for a finite treatment period of 52 weeks in patients with high-risk biochemically relapsed prostate cancer. In ...

The key finding was that men who received rectal spacers had a 50% lower risk of biochemical failure. In this video, Sean P. Collins, MD, PhD, a radiation oncologist at Tampa General Hospital in Tampa ...

Disitamab vedotin plus toripalimab nearly doubled progression-free and overall survival compared to chemotherapy in HER2-expressing la/mUC patients. The combination therapy showed a 64% reduction in ...

A focal point of the discussion was the ARANOTE trial, which examined darolutamide plus ADT versus ADT alone in men with metastatic hormone-sensitive prostate cancer who had not received chemotherapy ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...

The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia or death with a 50 ...

Cycling has multiple benefits, and steps can be taken to prevent genitourinary injury. Bicycling across the globe is increasing as a means of exercise and transportation. Clinicians need to be ...

In this interview, Parviz K. Kavoussi, MD, discusses his diagnostic work-up for patients who present with chronic testicular pain and describes conservative and surgical management approaches for the ...

Although low, men experienced a higher risk for erectile dysfunction and hypogonadism after being prescribed semaglutide for weight loss; however, further questions remain. Non-diabetic men treated ...

The survey examines urologists' treatment patterns and preferences for non–muscle invasive bladder cancer, providing valuable insights into current practices. Michael S. Cookson, MD, and Jason M.

The decline in total testosterone was observed even among men with normal body mass index. From 1999 to 2016, testosterone levels have declined in adolescent and young adult men (AYA), according to ...